• Molecular NameLercanidipine
  • Synonymlercanidipine
  • Weight611.739
  • Drugbank_IDDB00528
  • ACS_NO100427-26-7
  • Show 3D model
  • LogP (experiment)7.16
  • LogP (predicted, AB/LogP v2.0)7.29
  • pkaN/A
  • LogD (pH=7, predicted)6.44
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-5.86
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds14
  • TPSA116.7
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA calcium channel blocker of the dihydropyridine class.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability10.0
  • Protein binding98.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt undergoes extensive first-pass metabolism to inactive metabolites
  • Half life2~5 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityLercanidipine’s most commonly reported adverse effects are similar to those of other dihydropyridine calcium-channel blockers. They include edema, headache, asthenia, vertigo, palpitations, dizziness,flushing, and tachycardia.
  • LD50 (rat)LD50=39 (intravenous)
  • LD50 (mouse)LD50=440 (peroral)